dual agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-12. Numbers and descriptions here follow the published literature rather than marketing material.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
== External links == This page was reproduced (with modifications) with expressed consent from Dr. A. Malcolm Campbell. As of 2010, the original page can be found at Campbell AM (2003). "Protein Crystallization". Davidson, NC: Department of Biology, Davidson College.
=== Unclaimed Property Program === As secretary of revenue, Kennedy started an initiative to return unclaimed property to the people of Louisiana. At the time, nearly 500,000 people had valuable unclaimed property, such as old bank accounts, stocks, bonds, utility deposits and other lost or forgotten money that had been turned over to the state. Louisiana was one of 39 states to join an effort to return unclaimed property. Kennedy's Louisiana team hosted "Unclaimed Property Awareness Day" at the Lakeside Mall in Metairie, where shoppers claimed more than $365,000 in unclaimed property from the state. Kennedy also launched a website for Louisiana residents to collect unclaimed property online and continued to hold events throughout the state to help people find their unclaimed money. He continued the unclaimed property effort after being elected treasurer.
A further effect of isotretinoin on the brain involves retinoic acid function in the hypothalamus, the hormone regulatory centre of the brain and part of the hypothalamus-pituitary-adrenal axis, a key part of the body's stress response. Other brain regions regulated by retinoic acid and potentially disrupted by isotretinoin include the frontal cortex and the striatum.
Sources: en.wikipedia.org
1 March to 8 May The 4th Marine Regiment launched Operation Purple Martin against three PAVN regiments operating near the Vietnamese Demilitarized Zone (DMZ). The operation results in 347 PAVN killed and approximately 100 Marines killed.
But, for ruling out infections causes being one of the more important roles for clinical metagenomics it is essential to be capable to perform a deep enough sequencing to achieve adequate sensitivities. One way could be developing novel library preparation techniques.
=== Formal development never or not yet started === Small-molecule oxytocin receptor agonists (e.g., LIT-001, LIT-002) 15-Lipoxygenase (15-LOX; ALOX15) inhibitors (small-molecule indirect oxytocin-like drugs) (e.g., KNX-100 (SOC-1), KNX-101)
Naked monoclonal antibodies are antibodies without added elements. Most antibody therapies use this antibody type. Conjugated monoclonal antibodies are joined to another molecule, which is either cytotoxic or radioactive. The toxic chemicals are those typically used as chemotherapy drugs, but other toxins can be used. The antibody binds to specific antigens on cancer cell surfaces, directing the therapy to the tumor. Radioactive compound-linked antibodies are referred to as radiolabelled. Chemolabelled or immunotoxins antibodies are tagged with chemotherapeutic molecules or toxins, respectively. Research has also demonstrated conjugation of a TLR agonist to an anti-tumor monoclonal antibody.
Sources: en.wikipedia.org
== Regulation of enzymatic activity == SARM1's TIR domain is a multi-functional NAD(P)ase enzyme capable of hydrolyzing NAD+ or NADP, cyclizing NAD+ or NADP to form cADPR or cADPRP, and transglycosidation (base exchange) of NAD+ or NADP with free pyridines to form molecules such as NAADP. For NAD+, the transglycosidation (base exchange) activity of SARM1 extends beyond simple pyridines and includes many heterocyclic nucleophilic bases. SARM1's enzymatic activity can be regulated at the TIR domain orthosteric site by naturally occurring metabolites such as nicotinamide, NADP, and nicotinic acid riboside. Non-endogenous small chemical molecules have also been shown to inhibit SARM1's enzymatic activity at or near the orthosteric site. In addition, SARM1's enzymatic activity can be regulated by its allosteric site at the ARM domain, which can bind to NMN or NAD+. The ratio of NMN/NAD+ in cells determines SARM1's enzymatic activity. A chemically-modified cell permeable version of NMN, CZ-48, likely activates SARM1 via interacting with this allosteric region. Two long-studied neurotoxins, Vacor and 3-acetylpyridine, cause neurodegeneration by activating SARM1. Both Vacor and 3-acetylpyridine can be modified by NAMPT to become their mononucleotide versions (Vacor-MN or 3-AP-MN) that bind to SARM1's allosteric ARM domain region and activate its TIR domain NADase activity.
trimer A molecular aggregate consisting of three subunits. The term is often used to refer to protein complexes composed of three proteins, e.g. many membrane porins, or to individual proteins composed of three polypeptides. Compare monomer, dimer, and tetramer.
Flashing Flashing LEDs are used as attention seeking indicators without requiring external electronics. Flashing LEDs resemble standard LEDs but they contain an integrated voltage regulator and a multivibrator circuit that causes the LED to flash with a typical period of one second. In diffused lens LEDs, this circuit is visible as a small black dot. Most flashing LEDs emit light of one color, but more sophisticated devices can flash between multiple colors and even fade through a color sequence using RGB color mixing. Flashing SMD LEDs in the 0805 and other size formats have been available since early 2019. Flickering Simple electronic circuits integrated into the LED package have been around since at least 2011 which produce a random LED intensity pattern reminiscent of a flickering candle. Reverse engineering in 2024 has suggested that some flickering LEDs with automatic sleep and wake modes might be using an integrated 8-bit microcontroller for such functionally. Sometimes a flickering effect might happen due to an electric malfunction. Bi-color Bi-color LEDs contain two different LED emitters in one case. There are two types of these. One type consists of two dies connected to the same two leads antiparallel to each other. Current flow in one direction emits one color, and current in the opposite direction emits the other color. The other type consists of two dies with separate leads for both dies and another lead for common anode or cathode so that they can be controlled independently. The most common bi-color combination is red/traditional green.
Collin Whitfield Willson. Animal Welfare Veterinary Lead, Food Standards Agency. For services to Animal Welfare and to Veterinary Public Health in the Meat Industry. Christine Mary Windmill. Honorary Vice-President, TennisScotland. For services to Tennis. Rabbi Jonathan Wittenberg. Senior Rabbi, Masorti Judaism. For services to the Jewish Community and to Interfaith Relations. Carl Vivian Woodall. Lately Director of Facilities, House of Lords. For services to Parliament. Ian William James Woodroffe. Founder, easyfundraising. For services to Charitable Fundraising. Philip Graham Wynn. Chair, LEAF (Linking Environment and Farming). For services to Farming and to the Environment. Professor Julia Mary Yeomans FRS. Professor of Physics and Head, Rudolf Peierls Centre, University of Oxford. For services to Physics. Zehra Zaidi. For services to International Development, to Humanitarian Action and to Community Cohesion. Helen Margaret Zammit-Willson. Director, National Valuation Unit, Valuation Office Agency. For services to the Surveying Profession. International list Richard Allan, Director and Chief Executive Officer, The Mentor Initiative. For services to victims of war and natural disasters. Robert Berry, Director, Financial Reporting Authority, Cayman Islands. For services to the UK Sanctions Regime and Global Financial Standards in the Cayman Islands. Dr Ruth Lawson, Development Director and Chargé d'Affaires, British Embassy Khartoum, Sudan. For services to International Development and British Foreign Policy.
Labcorp Holdings Inc., operating under the brand name Labcorp, headquartered in Burlington, North Carolina, provides laboratory services used for diagnosis and healthcare decisions. It operates one of the largest clinical laboratory networks in the world and has operations in over 100 countries; although its operations are primarily in the U.S. Its Diagnostics Laboratories segment operates 2,000 patient service centers with more than 6,000 in-office phlebotomists in the United States. In addition to healthcare testing such as oncology testing, human immunodeficiency virus (HIV) genotyping and phenotyping, it provides testing for: employment, DNA testing to determine parentage and to determine immigration eligibility, environmental issues, wellness, toxicology, pain management, and medical drug monitoring. It also provides 50 tests that patients can complete at home. It processes over 160 million tests per year. Approximately 10% of this segment’s revenue are from the U.S. Medicare health insurance program. Its Biopharma Laboratory Services segment provides drug development, medical device and diagnostic development services to pharmaceutical, biotechnology, medical device, and diagnostic companies. In 2023, this division provided support to 84% of the new drugs and therapeutic products approved by the Food and Drug Administration. Labcorp performs its largest volume of specialty testing at its Center for Esoteric Testing in Burlington, North Carolina.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.